Cingulate Inc. - Common Stock (CING)
Frequently Asked Questions About Cingulate Inc. - Common Stock (CING)
How does Cingulate Inc. address patient needs?
Cingulate Inc. addresses patient needs by focusing on developing treatments that provide effective symptom management with reduced side effects, ultimately improving patient quality of life and adherence to medication.
How does Cingulate Inc. fund its operations?
Cingulate Inc. funds its operations through a combination of equity financing, grants, partnerships, and collaboration with other pharmaceutical companies, allowing it to invest in research and development.
How has Cingulate Inc. performed in the stock market?
Cingulate Inc.'s performance in the stock market has experienced fluctuations based on clinical progress, regulatory news, and overall investor sentiment, which are common in the biopharmaceutical industry.
Is Cingulate Inc. involved in any sustainability initiatives?
Cingulate Inc. emphasizes responsible practices and is committed to sustainability, focusing on ethical data management, responsible corporate governance, and community engagement to ensure they contribute positively to society.
What are Cingulate's main products or pipeline drugs?
Cingulate's main products focus on ADHD treatments, including Cingulate’s lead candidate, which combines an extended-release formulation to address the symptoms associated with ADHD in children and adults. They are also exploring additional pipeline candidates for related CNS disorders.
What are the competitive advantages of Cingulate Inc.?
Cingulate Inc.'s competitive advantages include its innovative technology platform for drug formulation, a focused research approach on ADHD, and a dedicated team with extensive industry experience, positioning it favorably in the biopharmaceutical landscape.
What are the future growth plans for Cingulate Inc.?
Cingulate Inc. plans to expand its pipeline of CNS treatments through continued investment in research and development, seeking to develop additional formulations, and possibly exploring new indications to address broader patient needs.
What challenges does Cingulate Inc. face?
Cingulate Inc. faces challenges typical of biopharmaceutical companies, including the high costs of drug development, regulatory hurdles, and the competitive nature of the CNS market, necessitating strategic planning and execution.
What clinical trials is Cingulate Inc. currently conducting?
Cingulate Inc. is actively conducting clinical trials to evaluate the safety and efficacy of its lead ADHD drug formulation. These trials are crucial for obtaining regulatory approval and bringing their therapies to market.
What does Cingulate Inc. do?
Cingulate Inc. is a biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders, particularly attention-deficit/hyperactivity disorder (ADHD). They utilize their proprietary technology platform to create drug formulations that can improve treatment efficacy and patient compliance.
What is the importance of Cingulate's R&D efforts?
Cingulate's R&D efforts are crucial as they fuel the discovery and development of new therapies that can better address the unique needs of individuals suffering from ADHD and related CNS disorders, ultimately contributing to improved therapeutic outcomes.
What is the mission statement of Cingulate Inc.?
Cingulate Inc. aims to transform the treatment landscape for ADHD and related CNS disorders by leveraging innovative technologies and a patient-centered approach to ensure effective and accessible therapies.
What is the significance of Cingulate’s proprietary technology?
Cingulate's proprietary technology allows for the development of customizable drug formulations that can optimize therapeutic outcomes by allowing for precision dosing and improved patient compliance, which is vital for managing chronic conditions.
What is the ticker symbol for Cingulate Inc.?
Cingulate Inc. is publicly traded under the ticker symbol 'CING' on the NASDAQ stock exchange, allowing investors to buy and sell shares of the company.
What partnerships does Cingulate Inc. have?
Cingulate Inc. has formed strategic partnerships with various academic institutions and pharmaceutical companies to enhance research capabilities and streamline the development of its drug candidates.
When was Cingulate Inc. founded?
Cingulate Inc. was founded in 2014, aiming to address unmet medical needs in the treatment of CNS disorders, particularly through its innovative drug formulations.
Where is Cingulate Inc. headquartered?
Cingulate Inc. is headquartered in Kansas City, Missouri, where it operates its business functions and manages its research and development activities.
Who are the key executives at Cingulate Inc.?
Cingulate Inc. is led by a knowledgeable team, including their CEO, Dr. John R. W. Houghton, and other experienced executives who bring extensive experience in pharmaceutical development and commercialization.
Who regulates Cingulate Inc.'s operations?
Cingulate Inc. operates under regulations set by the U.S. Food and Drug Administration (FDA), which oversees the clinical trial process and the approval of new medications to ensure they meet safety and efficacy standards.
What is the current price of Cingulate Inc. - Common Stock?
The current price of Cingulate Inc. - Common Stock is 4.110
When was Cingulate Inc. - Common Stock last traded?
The last trade of Cingulate Inc. - Common Stock was at 4:00 pm EDT on April 3rd, 2025